Gyre Therapeutics (GYRE) Interest Expenses (2010 - 2024)
Gyre Therapeutics (GYRE) posted quarterly Interest Expenses of $844000.0 for Q1 2026, up 32.91% year-over-year from $635000.0 in Q1 2025, and up 228.4% quarter-over-quarter from $257000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Interest Expenses (2010 - 2024) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Interest Expenses for 15 consecutive years, with $844000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 32.91% year-over-year to $844000.0; the TTM figure through Mar 2026 stood at $844000.0 (up 32.91% YoY), while the FY2025 annual figure was $88.6 million, down 53.47% from the prior year.
- Interest Expenses rose to $844000.0 in Q1 2026 per GYRE's latest filing, from $257000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $2.1 million in Q2 2024 and bottomed at -$905000.0 in Q4 2022.
- Historically, Interest Expenses has averaged $621588.2 across 5 years, with a median of $502000.0 in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses plunged 236.3% — and 2023, when it soared 1916.67%.
- Gyre Therapeutics' Interest Expenses stood at -$905000.0 in 2022, then jumped by 123.09% to $209000.0 in 2023, then grew by 15.31% to $241000.0 in 2024, then climbed by 6.64% to $257000.0 in 2025, then soared by 228.4% to $844000.0 in 2026.
- Business Quant data shows GYRE's Interest Expenses at $844000.0 in Q1 2026, $257000.0 in Q4 2025, and $1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 315,000.00 |
| Mar 31, 2023 | 643,000.00 |
| Dec 31, 2020 | 71,000.00 |
| Sep 30, 2020 | 7,000.00 |
| Dec 31, 2019 | -34,000.00 |
| Dec 31, 2015 | 22,000.00 |
| Sep 30, 2015 | 1.44 Mn |
| Jun 30, 2015 | 39,000.00 |
| Dec 31, 2014 | 3,000.00 |
| Sep 30, 2014 | 5,000.00 |
| Jun 30, 2014 | 6,000.00 |
| Mar 31, 2014 | 9,000.00 |
| Dec 31, 2013 | 10,000.00 |
| Sep 30, 2013 | 13,000.00 |
| Jun 30, 2013 | 14,000.00 |
| Mar 31, 2013 | 16,000.00 |
| Dec 31, 2012 | 18,000.00 |
| Sep 30, 2012 | 20,000.00 |
| Jun 30, 2012 | 22,000.00 |
| Mar 31, 2012 | 26,000.00 |